Mission Statement, Vision, & Core Values (2026) of Rohto Pharmaceutical Co.,Ltd.

Founded in 1889, Rohto Pharmaceutical Co., Ltd. has grown from a domestic OTC and skincare maker into a global health company operating in over 110 countries, with a product mix spanning eye care, topical medicines, skincare and functional foods and a bold strategic roadmap announced in 2023 as the ROHTO Group Comprehensive Management Vision 2030; that vision pairs ambitious commercial goals-targeting ¥415 billion in net sales by 2030-with a clear pivot into regenerative medicine and CDMO services, a commitment to sustainability backed by specific environmental and social targets through 2030, and core values centered on "health," honesty, customer service, teamwork and the company's guiding Seven Pledges, all of which frame Rohto's drive to deliver safe, research-backed products and connect people worldwide to greater well-being.

Rohto Pharmaceutical Co.,Ltd. (4527.T) - Intro

• Founded: 1889 (Osaka, Japan)
• Global presence: operations in 110+ countries
• Core product areas: eye care, skincare, topical medicines, functional foods
• Strategic horizon: 'ROHTO Group Comprehensive Management Vision 2030' (announced 2023)

• Mission: Enhance everyday well-being by delivering accessible, science-backed OTC and skincare solutions that improve quality of life.
• Vision (2030): Connect people to well-being via integrated product-service platforms, regenerative medicine capabilities and expanded CDMO offerings.
• Strategic pillars: Consumer health brand leadership, R&D-driven innovation (including regenerative medicine), geographic expansion, sustainability & social contribution.

• Carbon & energy: target to reduce greenhouse gas emissions and improve energy efficiency across manufacturing and logistics by 2030 (group-level percentage targets set under the 2030 roadmap).
• Resource circularity: commitments to reduce plastic packaging, increase recycled content and improve product take-back where applicable.
• Health access & social contribution: scale initiatives to improve eye health, skincare education and community health outreach in emerging markets.

• Core R&D remit: consumer OTC improvements, novel topical formulations, ophthalmic science and functional food efficacy.
• Emerging areas: active investments into regenerative medicine research and commercialization pathways, and expansion of contract development and manufacturing (CDMO) services to leverage formulation and manufacturing expertise.
• Organizational capability: in-house formulation platforms, clinical development teams and manufacturing scale that enable transitions from consumer health to specialty biologics/CDMO projects.

• Brand strength: flagship eye-care and skincare brands with high market recognition in Japan and select Asian markets.
• Geographic expansion: growth driven by ASEAN, Greater China and other emerging markets where over-the-counter and skincare demand is rising.
• Portfolio diversification: moving beyond OTC into regenerative therapies and CDMO to capture higher-margin, longer-term pharma demand.

• Revenue growth by region (Japan vs. international)
• R&D expense ratio and milestones in regenerative medicine programs
• CDMO contract wins and utilization rates of manufacturing capacity
• Progress on 2030 sustainability KPIs (emissions, packaging, social programs)

Rohto Pharmaceutical Co.,Ltd. (4527.T) - Overview

• Delivering health: development and global distribution of ophthalmic, dermatological, oral care, and OTC products designed to improve everyday well-being.
• Safety and function: rigorous R&D and quality control to ensure products meet high safety and efficacy standards.
• Societal contribution: aligning business growth with social sustainability-extending healthy lifespan and quality of life.
• Innovation pathway: expanding from consumer healthcare into regenerative medicine, biologics development, and CDMO to meet advanced medical needs.

• Global well-being leader: scale brands and therapeutic capabilities worldwide while maintaining Japan-origin quality and trust.
• Integrated healthcare solutions: combine OTC strengths with prescription, regenerative medicine, and contract development/ manufacturing (CDMO) to offer end-to-end solutions.
• Sustainable growth: invest in R&D and manufacturing capacity to support long-term health outcomes and steady shareholder value.

• Patient- and consumer-first thinking - prioritize real-world benefits and safety.
• Scientific rigor - evidence-based product development and continuous clinical evaluation.
• Integrity and compliance - regulatory excellence across markets.
• Collaboration and agility - partnerships in biopharma, academia, and industry to accelerate innovation (including CDMO alliances).
• Responsibility to society - sustainable practices and focus on extending healthy lifespans.

• R&D expansion: increased allocation to regenerative medicine programs and biologics process development.
• CDMO capability build-out: investment in GMP facilities and contract services to capture growing outsourcing demand from biotech partners.
• Global brand scaling: targeted international marketing and local registrations for flagship OTC and skincare lines.
• ESG integration: product stewardship, reduced environmental footprint in manufacturing, and community health programs.

• Unmet medical needs: Rohto leverages its R&D and manufacturing know-how to develop regenerative therapies that extend healthy lifespans, consistent with its mission to lead society to well-being.
• CDMO services: offering process development and manufacturing for biologics enables Rohto to partner with innovators, scale therapies faster, and diversify revenue while advancing public health.
• Commercial pathway synergy: consumer health brands provide cashflow and market insights that support long-term investment into higher-risk, higher-impact regenerative programs.

Rohto Pharmaceutical Co.,Ltd. (4527.T) - Mission Statement

• Deliver accessible, science-backed health and beauty solutions that address daily needs and societal health challenges.
• Drive sustainable growth while contributing to community wellbeing and environmental stewardship.
• Expand domains beyond OTC ophthalmics and skincare into functional foods, regenerative medicine, and CDMO (contract development and manufacturing organization) services.
• Foster a corporate culture of mutual inspiration, continuous learning, and agility in response to change.

Vision Statement - strategic pillars and numeric targets

• Net sales target: 415 billion yen by 2030 - a central corporate growth benchmark.
• Business expansion into functional foods, regenerative medicine, and CDMO services - diversifying revenue streams.
• Priority on innovation-led product pipelines, with R&D investments scaled to sustain global competitiveness.

How the vision translates into action

• Product innovation: prioritizing eye care and skincare product lines while accelerating pipelines in functional foods and regenerative therapies.
• CDMO development: investing in manufacturing capacity and technical capabilities to serve external biopharma partners as a growth lever.
• Sustainability and social contribution: aligning packaging, sourcing, and operations with reduced environmental footprint and community health initiatives.
• Science-driven culture: increasing cross-functional R&D collaboration and external partnerships to turn academic and clinical advances into commercial solutions.

Rohto Pharmaceutical Co.,Ltd. (4527.T) - Vision Statement

• Health-centered purpose: prioritize products and services that improve physical, mental and social well-being.
• Global accessibility: expand product reach while maintaining culturally appropriate care and safety standards.
• Sustainable coexistence: integrate environmental stewardship into manufacturing, packaging, and supply chains.
• Innovative science: accelerate R&D to bring safer, more effective OTC, skincare, and ophthalmic products to market.

• Health as guiding value - improving lives through products and services that support physical, mental, social and environmental health.
• Honesty & integrity - transparent governance, ethical interactions with partners, and adherence to regulatory and quality standards.
• Customer service orientation - proactive support, post‑market monitoring, and product education to ensure safe, effective use.
• Teamwork & collaboration - cross‑functional collaboration within R&D, manufacturing and global marketing to scale impact.
• Seven Pledges - daily behavioral guide emphasizing service to society, continuous self-improvement, energetic action, and support for colleagues.
• Sustainability commitment - concrete actions toward lower emissions, reduced waste, eco‑friendly packaging, and community coexistence.

• Support society and customers through sincere effort.
• Value honest, open relationships with colleagues and partners.
• Engage in continuous self‑improvement and learning.
• Act with energy and initiative in daily work.
• Deliver quality and safety as non‑negotiable principles.
• Respect the environment and strive for sustainable operations.
• Contribute to communities where Rohto operates.

• Environmental measures: initiatives to reduce energy intensity in manufacturing, move toward recycled and minimal packaging, and lifecycle assessments for key products.
• Community engagement: local public health education, donation programs, and disaster relief support where Rohto operates.
• Governance & compliance: ethics training, supplier audits, and stringent quality systems to protect consumers and uphold honesty.

• Product development routinely includes health impact assessments (safety, ease of use, accessibility).
• Customer service KPIs are tied to product returns, adverse event follow‑up rates, and satisfaction scores.
• Sustainability KPIs track energy, water, waste, and packaging footprint across major production sites.